Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Dow Suffers Through Downward GDP Revisions as Merck, Pfizer Lead Decliners

The Dow Jones Industrials (DJINDICES: ^DJI  )  was down 86 points as of 12:30 p.m. EDT. The most recent numbers on international trade as of March just came in; due to the differences between the Commerce Department's initial assumptions about trade data and the actual figures, many analysts reduced their estimates of final first-quarter U.S. GDP downward. With a range of -0.2% to -0.8% comparing unfavorably to the government's preliminary figure of +0.2%, the big question remains whether the economic hit was temporary due to the weather or symptomatic of longer-term issues. Leading the Dow downward this afternoon were Merck (NYSE: MRK  ) and Pfizer (NYSE: PFE  ) , while energy stocks were relatively strong.

Source: Merck.

Merck dropped more than 2% after the drugmaker announced that it would sell its consumer drug division to Germany's Bayer for $14.2 billion in cash. The move is consistent with Merck's overall strategic direction in narrowing its scope to emphasize its prescription pharmaceutical division and vaccine production, which have been far more lucrative areas for the pharma industry and have much greater growth prospects. Shareholders should get roughly half of the proceeds from the sale in the form of stock buybacks, while Merck plans to spend the other half on research and development or on making acquisitions to bolster its pipeline prospects. Yet even though Merck also said that its MK-3475 advanced melanoma treatment received priority review designation, investors didn't respond favorably in the short term to the news, suggesting that shareholders want even more dramatic strategic moves in order to send the stock higher after good gains so far in 2014.

Pfizer fell 1.4% as the company continues to wrangle with its own merger and acquisition plans. So far, buyout target AstraZeneca has shown no signs of going down without a fight, with the British company arguing now that its long-term prospects are good and that shareholders should remain patient with the existing corporate structure rather than letting Pfizer reap the benefits with an opportunistic takeover bid. Pfizer shareholders initially liked the idea of a combination, but as it becomes clear that even a successful bid won't necessarily lead to a smooth transition, investors appear to be cooling to the idea. At this point, it's unclear what would persuade AstraZeneca to accept a bid, and that uncertainty isn't making Pfizer shareholders happy -- especially with so much in cost savings and tax benefits at stake.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2945487, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:45:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:55 PM
^DJI $16643.01 Down -11.76 -0.07%
MRK $55.37 Up +0.42 +0.76%
Merck & Co., Inc. CAPS Rating: ****
PFE $32.66 Down -0.60 -1.80%
Pfizer CAPS Rating: ****